An inhibitor of PDE5, tadalafil, has been demonstrated to have a dramatic and durable anti-myeloma immune and clinical response in a patient with end-stage relapsed/refractory MM (Noonan et al., 2014). Here, PDE5A is linked to plasma cell myeloma.